↓ Skip to main content

Ovarian Cancer

Overview of attention for book
Cover of 'Ovarian Cancer'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Potential and Limitations in Early Diagnosis of Ovarian Cancer
  3. Altmetric Badge
    Chapter 2 SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
  4. Altmetric Badge
    Chapter 3 Classification of Ovarian Cancer: A Genomic Analysis
  5. Altmetric Badge
    Chapter 4 Ovarian Cancer
  6. Altmetric Badge
    Chapter 5 Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.
  7. Altmetric Badge
    Chapter 6 MicroRNA in Human Cancer: One Step Forward in Diagnosis and Treatment
  8. Altmetric Badge
    Chapter 7 Ovarian Carcinogenesis: An Alternative Hypothesis
  9. Altmetric Badge
    Chapter 8 BRCA1-Induced Ovarian Oncogenesis
  10. Altmetric Badge
    Chapter 9 Role of p53 and Rb in Ovarian Cancer
  11. Altmetric Badge
    Chapter 10 Ovulatory Factor in Ovarian Carcinogenesis
  12. Altmetric Badge
    Chapter 11 Gynecologic Oncology Group (GOG-USA) Trials in Ovarian Cancer
  13. Altmetric Badge
    Chapter 12 Intraperitoneal Chemotherapy for Ovarian Cancer
  14. Altmetric Badge
    Chapter 13 Ovarian Cancer: Can We Reverse Drug Resistance?
  15. Altmetric Badge
    Chapter 14 Syngeneic Mouse Model of Epithelial Ovarian Cancer: Effects of Nanoparticulate Paclitaxel, Nanotax®
  16. Altmetric Badge
    Chapter 15 Individualized Molecular Medicine: Linking Functional Proteomics to Select Therapeutics Targeting the PI3K Pathway for Specific Patients
  17. Altmetric Badge
    Chapter 16 Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer
  18. Altmetric Badge
    Chapter 17 Nanoparticle Delivery of Suicide DNA for Epithelial Ovarian Cancer Therapy
  19. Altmetric Badge
    Chapter 18 Biological Therapy with Oncolytic Herpesvirus
  20. Altmetric Badge
    Chapter 19 Cancer Immunotherapy: Perspectives and Prospects
  21. Altmetric Badge
    Chapter 20 Regulatory T Cells: A New Frontier in Cancer Immunotherapy
  22. Altmetric Badge
    Chapter 21 Inhibitory B7 Family Members in Human Ovarian Carcinoma
  23. Altmetric Badge
    Chapter 22 Role of Vascular Leukocytes in Ovarian Cancer Neovascularization
  24. Altmetric Badge
    Chapter 23 Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a New Target Molecule for Cancer Therapy
Attention for Chapter 2: SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

patent
2 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
Chapter number 2
Book title
Ovarian Cancer
Published in
Advances in experimental medicine and biology, January 2008
DOI 10.1007/978-0-387-68969-2_2
Pubmed ID
Book ISBNs
978-0-387-68966-1, 978-0-387-68969-2
Authors

Ingegerd Hellstrom, Karl Erik Hellstrom, Hellstrom, Ingegerd, Hellstrom, Karl Erik

Abstract

Assays measuring SMRP (mesothelin) and HE4 (a secreted protease) in serum and other body fluids (including urine for SMRP) are likely to be clinically useful for patients with ovarian cancer, as data indicate that they complement CA125 for diagnosis and monitoring of patients. Both markers have temporal stability, as does CA125, which may be utilized to facilitate earlier diagnosis by performing longitudinal studies on high risk subjects. Preliminary data show autoantibodies to native mesothelin in some patients with ovarian carcinoma and in some healthy women. We are presently studying their relationship to the patients' clinical state to learn whether measurements of antibody levels provide information that can aid diagnosis and monitoring of treated patients. Prospective studies are needed to establish the clinical relevance of our findings.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 4%
Netherlands 1 4%
Unknown 25 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 19%
Student > Master 4 15%
Student > Ph. D. Student 3 11%
Student > Doctoral Student 2 7%
Other 2 7%
Other 5 19%
Unknown 6 22%
Readers by discipline Count As %
Medicine and Dentistry 10 37%
Agricultural and Biological Sciences 4 15%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Chemistry 1 4%
Other 1 4%
Unknown 9 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2014.
All research outputs
#4,696,396
of 22,788,370 outputs
Outputs from Advances in experimental medicine and biology
#809
of 4,933 outputs
Outputs of similar age
#22,119
of 156,208 outputs
Outputs of similar age from Advances in experimental medicine and biology
#10
of 33 outputs
Altmetric has tracked 22,788,370 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,933 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,208 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.